Cannon CP, Pratley R, Dagogo-Jack S, et al. - To ascertain the cardiovascular impacts of ertugliflozin, an inhibitor of sodium–glucose cotransporter 2, researchers undertook this multicenter, double-blind trial with patients whom had type 2 diabetes and atherosclerotic cardiovascular disease. Participants were randomized to receive 5 mg or 15 mg of ertugliflozin or placebo once daily. The primary outcome was major adverse cardiovascular events (defined as a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke). This study involved 8,246 patients who were followed-up for a mean of 3.5 years. Findings demonstrated the noninferiority of ertugliflozin to placebo with respect to major adverse cardiovascular events in patients suffering from type 2 diabetes and atherosclerotic cardiovascular disease. A major adverse cardiovascular event was seen in 653 of 5,493 patients (11.9%) in the ertugliflozin group and in 327 of 2,745 patients (11.9%) in the placebo group. Death from cardiovascular causes or hospitalization for heart failure occurred in 444 of 5,499 patients (8.1%) in the ertugliflozin group and in 250 of 2,747 patients (9.1%) in the placebo group.